The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight

The psoriasis clinical trial analysis report delivers important insights into ongoing research of 100+ pipeline psoriasis drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

New York, USA, April 14, 2026 (GLOBE NEWSWIRE) — The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight

The psoriasis clinical trial analysis report delivers important insights into ongoing research of 100+ pipeline psoriasis drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

DelveInsight’s ‘Psoriasis Pipeline Insight 2026’ report provides comprehensive global coverage of pipeline therapies for psoriasis across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the psoriasis domain.

Psoriasis Clinical Trial Analysis Summary

• DelveInsight’s psoriasis pipeline report depicts a robust space with 90+ active players working to develop 100+ pipeline psoriasis drugs. 
• Key psoriasis companies, such as Can-Fite Biopharma, MetrioPharm, Haisco Pharmaceutical Group, Oruka Therapeutics, Inc., Seismic Therapeutic AU, Usynova Pharmaceuticals, Takeda, Soligenix, Inc., FibroBiologics, Inc., SFA Therapeutics, Inc, InventisBio Co., Ltd, Jiangsu HengRui Medicine Co., Ltd., InnoCare Pharma, LAPIX Therapeutics Inc., Sareum Holdings, CSPC Ouyi Pharmaceutical Co., Ltd., Huabo Biopharm, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Xantho Biotechnology Co., LTD, Artelo Biosciences, and others, are evaluating new psoriasis drugs to improve the treatment landscape.
• Promising pipeline psoriasis therapies, such as Piclidenoson, MP1032, HSK44459, ORKA-001, S-4321, UA-026, Zasocitinib, SGX302, CYPS317, SFA-002, D-2570, RSS0393, ICP-488, LPX-TI641, SDC-1801, SYHX1901, HB0017, TQH2929, GM-XAN003, ART26.12, and others, are in different phases of psoriasis clinical trials.
• Approximately 40+ psoriasis drugs are in the late and mid stages of development.
• Notable MoAs in psoriasis clinical trials include Adenosine A3 receptor agonists, Macrophage modulators, Type 4 cyclic nucleotide phosphodiesterase inhibitors, Interleukin-23 subunit p19 inhibitors, Fc gamma receptor IIB agonists, Programmed cell death 1 receptor agonists, Interleukin 17 inhibitors, TYK2 kinase inhibitors, and others.

Request a sample and discover the recent advances in psoriasis drug development @ https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight

What is Psoriasis?

Psoriasis is a long-lasting, non-contagious condition in which the immune system mistakenly accelerates the life cycle of skin cells, causing them to build up rapidly on the surface. This leads to thick, red, inflamed patches of skin covered with silvery-white scales, commonly appearing on the elbows, knees, scalp, and lower back. The condition is driven by immune-mediated inflammation and is often associated with symptoms like itching, burning, and discomfort. While the exact cause is not fully understood, it is linked to a combination of genetic predisposition and environmental triggers such as stress, infections, or certain medications. Psoriasis can vary in severity and may also be associated with related conditions like psoriatic arthritis, affecting joints in some individuals.

Find out more about psoriasis drugs @ Psoriasis Treatment

A snapshot of the Pipeline Psoriasis Drugs mentioned in the report:

Learn more about the emerging psoriasis therapies @ Psoriasis Clinical Trials 

According to Stuti Mahajan, consulting manager at DelveInsight, psoriasis continues to place a lasting burden on patients, driving the need for effective long-term management. Growing prevalence, better diagnosis, and rising demand for targeted, safer therapies are fueling market momentum, while ongoing innovation in biologics and novel treatments is set to sustain strong future growth.

Recent Developments in Psoriasis Treatment Space

• In March 2026, InnoCare Pharma announced the completion of patient enrollment in the Phase III clinical study of ICP-488 in psoriasis.
• In February 2026, the International Federation of Psoriasis Associations (IFPA) and the WHO Foundation signed a multi-year collaboration agreement supporting WHO efforts to strengthen global understanding, diagnosis, and care for psoriasis.
• In January 2026, Alumis Inc. announced positive topline results from its Phase III ONWARD1 and ONWARD2 clinical trials of envudeucitinib, a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate-to-severe plaque psoriasis.
• In January 2026, Oruka Therapeutics announced the initiation of the EVERLAST-B trial of ORKA-001. The first patients were dosed in EVERLAST-B in December 2025.
• In December 2025, FibroBiologics, Inc. announced the filing of a Phase I/II Investigational New Drug (IND) application with the US Food and Drug Administration (FDA), seeking regulatory clearance to initiate clinical trials of CYPS317 for the treatment of moderate to severe psoriasis.
• In December 2025, Takeda announced positive topline results for the two pivotal Phase III randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). 
• In December 2025, Soligenix, Inc. announced extended results of its ongoing Phase IIa trial of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis. In this extension (Cohort 3) of the exploratory phase of the study, an additional four patients were enrolled and treated with an improved topical gel formulation of synthetic hypericin.
• In September 2025, Oruka Therapeutics, Inc. announced interim data from its Phase I trial of ORKA-001, the Company’s long-acting IL-23p19 antibody, in a late-breaking abstract at the European Academy of Dermatology and Venerology (EADV) Congress in Paris, France. 
• In April 2025, Seismic Therapeutic, Inc., announced the dosing of the first healthy subject cohort in a Phase I clinical trial of S-4321, a novel bifunctional antibody for the treatment of a range of autoimmune diseases.
• In March 2025, Can-Fite BioPharma Ltd. announced that it initiated a pivotal Phase III psoriasis study of its oral drug Piclidenoson with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) – approved clinical study protocol. 
• In March 2025, SFA Therapeutics, Inc., announced positive data from its Phase Ib clinical trial of oral drug candidate SFA-002 in patients with mild-to-moderate psoriasis.

Scope of the Psoriasis Pipeline Report 

• Coverage: Global 
• Psoriasis Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Psoriasis Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Psoriasis Therapeutics Assessment By Route of Administration: Intravenous, Subcutaneous, Oral, Intramuscular
• Psoriasis Therapeutics Assessment By Molecule Type: Monoclonal antibody, Small molecule, Peptide
• Psoriasis Therapeutics Assessment By Mechanism of Action: Adenosine A3 receptor agonists, Macrophage modulators, Type 4 cyclic nucleotide phosphodiesterase inhibitors, Interleukin-23 subunit p19 inhibitors, Fc gamma receptor IIB agonists; Programmed cell death 1 receptor agonists, Interleukin 17 inhibitors, TYK2 kinase inhibitors, and others
• Key Psoriasis Companies: Can-Fite Biopharma, MetrioPharm, Haisco Pharmaceutical Group, Oruka Therapeutics, Inc., Seismic Therapeutic AU, Usynova Pharmaceuticals, Takeda, Soligenix, Inc., FibroBiologics, Inc., SFA Therapeutics, Inc, InventisBio Co., Ltd, Jiangsu HengRui Medicine Co., Ltd., InnoCare Pharma, LAPIX Therapeutics Inc., Sareum Holdings, CSPC Ouyi Pharmaceutical Co., Ltd., Huabo Biopharm, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Xantho Biotechnology Co., LTD, Artelo Biosciences, and others.
• Key Psoriasis Pipeline Therapies: Piclidenoson, MP1032, HSK44459, ORKA-001, S-4321, UA-026, Zasocitinib, SGX302, CYPS317, SFA-002, D-2570, RSS0393, ICP-488, LPX-TI641, SDC-1801, SYHX1901, HB0017, TQH2929, GM-XAN003, ART26.12 and others.

Dive deep into rich insights for new psoriasis treatments, visit @ Psoriasis Drugs

Table of Contents

For further information on the psoriasis cure research, reach out @ Medication for Psoriasis Treatment

Related Reports

Psoriasis Market

Psoriasis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psoriasis companies, including Takeda, Nimbus Therapeutics, Johnson & Johnson Innovative Medicine, Protagonist Therapeutics, Can-Fite BioPharma, Alumis, SFA Therapeutics, and others.

JAK Inhibitors Market

JAK Inhibitors Market Size, Target Population, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key JAK inhibitors companies, including Pfizer, AbbVie, Galapagos, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., MaxiNovel Pharmaceuticals, and others.

TNF-alpha Inhibitors Market

TNF-alpha Inhibitors Market Size, Target Population, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key TNF-alpha Inhibitors companies, including AbbVie, Amgen, Johnson & Johnson, Pfizer, UCB, Eli Lilly, Novartis, Merck, Sanofi, Boehringer Ingelheim, Samsung Bioepis, Celltrion, and others.

Interleukin-17 Inhibitors Market

Interleukin-17 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key IL-17 inhibitors companies, including MoonLake Immunotherapeutics, Affibody Medical AB, SFA Therapeutics, DICE Therapeutics, Eli Lilly, UCB Pharma, Novartis, AstraZeneca, Bausch Health, Kyowa Kirin, LEO Pharma, and others.

Plaque Psoriasis Market

Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key plaque psoriasis companies, including Suzhou Zelgen Biopharmaceuticals, Sun Pharmaceutical Industries Limited, GC Cell Corporation, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

CONTACT: Contact Us Shruti Thakur  [email protected]  +14699457679

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. DailyIndiaNews.com takes no editorial responsibility for the same.